Harvard Bioscience Inc. announced it has received a notification from the Nasdaq Stock Market indicating it has been granted an additional 180-day extension, until March 30, 2026, to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The extension follows the company's transfer from the Nasdaq Global Market to the Nasdaq Capital Market, effective October 3, 2025. If Harvard Bioscience's stock closes at or above $1.00 for at least 10 consecutive business days before the deadline, it will regain compliance. Failure to do so could result in delisting, although the company would have the right to appeal any delisting decision. The stock will continue trading under the symbol "HBIO."
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harvard Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-006260), on October 03, 2025, and is solely responsible for the information contained therein.